Enter inventor name

Wayne D Bowen

This inventor holds 16 USPTO granted patents. Top assignees: The United States of America as Represented by the Department of Health, Research Corporation Technologies, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1992-2003.

USPTO Granted Patents = 16

% Patents Active = 87.5

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 185(Granted Patents)

Location History:

East Providence, RI (US) (1992 - 1998)
Derwood, MD (US) (1994 - 2003)

Company Filing History:

7 out of 1,217

The United States of America as Represented by the Department of Health

patents

5 out of 366

Research Corporation Technologies, Inc.

patents

3 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

G.d. Searle & Company

patents

where one patent can have more than one assignee

Years Active: 1992-2003

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6656930 - Aralkyl diazabicycloalkane derivatives for CNS disorders (2003-12-02),

2. 6517811 - Compounds for cancer imaging and therapy (2003-02-11),

3. 6447748 - Benzamide compounds for cancer imaging and therapy (2002-09-10),

4. 6310064 - Aralkyl diazabicycloalkane derivatives for CNS disorders (2001-10-30),

5. 6015543 - Benzamide compounds containing a heterocyclic ring for tumor imaging and (2000-01-18),

6. 5993777 - Benzamide compounds for cancer imaging and therapy (1999-11-30),

7. 5958920 - Aralkyl diazabicycloalkane derivatives for CNS disorders (1999-09-28),

8. 5911970 - Methods for cancer imaging and therapy using benzamine compounds (1999-06-15),

9. 5856318 - Nitrogen-containing cyclohetero cyclo-heteroaminoaryl derivatives for (1999-01-05),

10. 5739158 - Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS (1998-04-14),

11. 5679679 - Aralkyl diazabicycloalkane derivatives for CNS disorders (1997-10-21),

12. 5679673 - Aralkyl bridged diazabicycloalkane derivatives for CNS disorders (1997-10-21),

13. 5656625 - Nitrogen-containing cyclohetero cycloheteroaminoaryl derivatives for CNS (1997-08-12),

14. 5571832 - Nitrogen-containing cyclohetero alkylamino aryl derivatives for CNS (1996-11-05),

15. 5346908 - Nitrogen-containing cyclohetero cycloheteroaminoaryl derivatives for CNS (1994-09-13),

Title: Wayne D Bowen: Innovator in CNS Disorders and Cancer Therapy

Introduction

Wayne D Bowen is a notable inventor based in Derwood, MD (US), recognized for his significant contributions to the fields of central nervous system (CNS) disorders and cancer therapy. With a total of 16 patents to his name, Bowen has made strides in developing innovative compounds aimed at treating serious health conditions.

Latest Patents

Among his latest patents, Bowen has developed aralkyl diazabicycloalkane derivatives specifically designed for the treatment of CNS disorders. These compounds are particularly relevant for conditions such as cerebral ischemia, psychosis, and convulsions. Additionally, he has created compounds that target cancer cells, including lung, colon, renal, prostate, breast carcinomas, and more. These compounds not only have therapeutic potential but also serve as agents for diagnostic imaging, enhancing the detection and treatment of tumors.

Career Highlights

Bowen's career has been marked by his work with the United States of America as represented by the Department of Health and Research Corporation Technologies, Inc. His innovative research has led to advancements in medical treatments that address critical health issues.

Collaborations

Throughout his career, Bowen has collaborated with esteemed colleagues, including Brian R De Costa and Kenner C Rice, contributing to the development of groundbreaking medical solutions.

Conclusion

Wayne D Bowen's work exemplifies the impact of innovation in medicine, particularly in addressing CNS disorders and cancer treatment. His patents reflect a commitment to improving health outcomes through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]